Exelixis, Inc. 10-Q Summary: Period Ended June 30, 2004
Business Context and Reporting Period
This is a Quarterly Report on Form 10-Q for Exelixis, Inc., a biotechnology company focused on developing pharmaceutical products for cancer and other serious diseases. The report covers the three and six-month periods ended June 30, 2004. The company operates primarily through research and development activities and collaborations with major pharmaceutical and agrochemical companies.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2004 | Six Months Ended June 30, 2004 | Balance Sheet (June 30, 2004) |
|---|---|---|---|
| Total Revenues | $12,559 | $24,451 | - |
| Net Loss | $(29,291) | $(58,134) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.41) | $(0.81) | - |
| Cash and Cash Equivalents | - | - | $38,924 |
| Short-term Investments | - | - | $123,722 |
| Total Current Assets | - | - | $170,239 |
| Total Liabilities | - | - | $180,077 |
| Stockholders' Equity | - | - | $107,116 |
| Accumulated Deficit | - | - | $(440,262) |
| Net Cash Used in Operating Activities | - | $(63,157) | - |
Material Changes vs. Prior Period
- Revenues: Total revenues decreased by 3% for both the three-month and six-month periods compared to the prior year. This decline was primarily due to the conclusion of the collaboration with Protein Design Labs in May 2003, partially offset by milestone revenue from the Bristol-Myers Squibb collaboration.
- Operating Expenses: Research and development (R&D) expenses increased by 6% ($1.9 million) for the quarter and 9% ($5.8 million) for the six months. Increases were driven by consulting and professional fees associated with advancing clinical trials (XL119 Phase 3, XL647 Phase 1) and preclinical testing.
- Restructuring Charges: The company recorded a restructuring charge of $1.7 million in the second quarter of 2004, related to a reduction in force of 62 employees. Additionally, $537,000 was recorded for the six-month period related to a 2003 restructuring plan.
- Liquidity: Cash and cash equivalents decreased significantly from $111.8 million at December 31, 2003, to $38.9 million at June 30, 2004, reflecting a net decrease of $72.9 million driven by operating losses and investing activities.
Guidance, Outlook, and Risks
- Clinical Pipeline: The company initiated a Phase 3 trial for XL119 (bile duct tumors) and a Phase 1 trial for XL647. An IND was filed for XL999. The company expects to file INDs for XL844, XL820, and XL880 in the first half of 2005.
- Liquidity Outlook: Management anticipates that current cash, investments, and collaborator funding will support operations for at least the next 18 months. However, the company expects to incur substantial losses for the foreseeable future and may need to raise additional capital.
- Restructuring: A consolidation of research organizations was implemented to optimize the generation of new drug applications. The company does not expect material future expenses related to this specific restructuring.
- Risks: Key risks include the need for additional financing, the uncertainty of clinical trial results, dependence on third-party manufacturers and collaborators, and the lengthy regulatory approval process. The company has no experience in sales and marketing and relies on collaborators for commercialization.
Investor Verification Checklist
- Verify the sufficiency of the $170.3 million in liquid assets to fund operations through the projected 18-month runway, considering the high burn rate ($63.2 million operating cash outflow in six months).
- Monitor the progress and results of the Phase 3 trial for XL119 and the Phase 1 trials for XL647 and XL999, as these are critical for future revenue potential.
- Review the status of key collaborations (Bristol-Myers Squibb, GlaxoSmithKline, Bayer) and the potential impact of expiring agreements on future revenue streams.
- Assess the impact of the $1.7 million restructuring charge and the reduction of 62 employees on the company's ability to execute its R&D pipeline.
- Confirm the company's ability to secure third-party manufacturing capacity for clinical trials, given its lack of internal manufacturing capabilities.